

July 28, 2021

To.

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India.

CIN: L85195TG1984PLC004507

Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com

The Secretary/Executive Director
BSE Limited
National Stock Exchange of India Limited
New York Stock Exchange, Inc.
NSE-IFSC Limited

Dear Sir/Madam,

<u>Sub:</u> Newspaper advertisement regarding financial results for the quarter ended June 30, 2021

Pursuant to Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulation, 2015, as amended, please find enclosed copies of newspaper advertisement regarding the financial results of the company for the quarter ended June 30, 2021 as published in Business Standard and Andhra Prabha on July 28, 2021.

This is for your information and records.

With regards,

Company Secretary

Encl: as above

Business Standard - July 28, 2021





Extract of unaudited financial results of Dr. Reddy's Laboratories Limited and its subsidiaries for the quarter ended 30 June 2021 prepared in compliance with Indian Accounting Standards

		All	amounts	in	Indian	Rupeea	millions
--	--	-----	---------	----	--------	--------	----------

		Consolidated			
SI. No.	Particulars	Quarter ended 30.06.2021 (Unaudited)	Quarter ended 30.06.2020 (Unaudited)	Year ended 31.03.2021 (Audited)	
1	Total Revenue from operations	49,451	44,265	190,475	
2	Net Profit for the period (before Tax, Exceptional and/or Extraordinary items)	5,558	9,005	28,835	
3	Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	5,556	9,005	28,835	
4	Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	3,804	5,946	19,516	
5	Total Comprehensive Income for the period	2,959	6,728	24,916	
6	Equity Share Capital	832	831	832	
7	Reserves (excluding Revaluation Reserve)			175,585	
В	Earnings per share (in Rupees) per Rs. 5'- share				
	Besic	22,96	35.67	117.67	
	Diluted	22.89	35,78	117,34	

		Standalone			
SI. No.	Particulars	Quarter ended 30.06.2021 (Unaudited)	Quarter ended 30.06.2020 (Unaudited)	Year ended 31.03.2021 (Audited)	
1	Total Revenue from operations	34,335	32,444	133,491	
2	Net Profit for the period (before Tax, Exceptional and/or Extraordinary Items)	5.445	13,617	30,562	
3	Net Profit for the period before tax (after Exceptional and/or Extraordinary items)	5,445	13,617	30,562	
4	Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	4,134	9,502	21,864	
5	Total Comprehensive Income for the period	3,790	9,733	22,405	
6	Equity Share Capital	832	831	832	
7	Reserves (excluding Revaluation Reserve)			169,005	
Ð	Earnings per share (in Rupees) per Rs. 5'- share				
	Basic	24.94	57,31	131.64	
	Diluted	24.87	57.18	131,46	

Note s:

1 The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchanges website; www.beeindia.com and www.nseindia.com and also on the Company's website; www.direddys.com.

website: www.beeindia.com and www.neeindia.com and also on the Company's website: www.direddys.com.

The unaudited results have been reviewed by the Audit Committee of the Board and approved by the Board of Directors of the Company at their meeting held on 27 July 2021.

By order of the Board For Dr. Reddy's Laboratories Limited


Place: Hyderabad Date: 27July 2021 GV Presed Co-Chairman & Managing Direcor

Dr. REDDY'S LABORATORIES LIMITED

Regd. Office: 8-2-337, Road No.3, Banjara Hills, Hyderabad - 500 034, Telangana, India CIN: L85195TG1984PLC004507, Tel: 91 40 4900 2900, Fax: 91 40 4900 2999 email: shares@drraddys.com, website: www.drraddys.com



Andhra Prabha - July 28, 2021



Extract of unaudited financial results of Dr. Reddy's Laboratories Limited and its subsidiaries for the quarter ended 30 June 2021 prepared in compliance with Indian Accounting Standards

Alliamouni	na ins	dodina	Di Maina	million
NE ARTHUSINE	23 H 4	S KINDLE	LINDIGES	CHIMICAN:

		Consolidated			
SI. No.	Párticulars	Quarter ended 30.06.2021 (Unaudited)	Quarter ended 30.06.2020 (Unaudited)	Year ended 31.03.2021 (Audited)	
1 2 3 4 5 6 7	Total Revenue from operations Net Proifi for the period (before Tax, Exceptional and/or Extraordinary items) Net Proifi for the period before tax (effer Exceptional and/or Extraordinary items) Net Proifi for the period after tax (effer Exceptional and/or Extraordinary items) Not Proifi for the period after tax (effer Exceptional and/or Extraordinary items) Total Comprehensive income for the period Equity Share Capital Reserves (excluding Revaluation Reserve)	49,451 5,658 5,658 3,604 2,959 632	44,265 9,005 9,005 5,946 6,728 áár	190,475 28,835 28,835 19,516 24,916 632 175,585	
8	Earnings per chare (in Rupees) per Rs. 54-share Basic Diuted	22.95 22.89	35.87 35.78	117.67 117.38	

		Standalone			
SI. No.	Particulara	Quarter ended 30.06.2021 (Unaudited)	Quarter ended 30.06.2020 (Unaudited)	Year ended 31,03,2021 (Audited)	
1 2 3 4	Total Revenue from operations Net Profit for the period (before Tax, Exceptional and/or Extraordinary items) Net Profit for the period before tax (after Exceptional and/or Extraordinary items) Net Profit for the period after tax (after Exceptional and/or Extraordinary items)	34,335 5,445 5,445 4,134	32,444 13,617 13,617 9,502	133,491 30,562 30,662 21,864	
.5 -6	Total Comprehensive income for the period	3,790 832	9,733	22,405 832	
7	Reserves (excluding Revaluation Reserve)	802	931	169,005	
a	Earnings per share (in Rupess) per Rs. 5/- share Basic Düluted	24.94 24.87	57.31 57.18	131.84 131.46	

The above is an extract of the detailed formal of Quarterly Financial Results filled with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Regulations). Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchanges wabsite; www.treshdia.com and www.reshidia.com and also on the Company's website; www.dreddys.com.
The unaudited results have been reviewed by the Audit Comsettee of the Board and approved by the Board of Directors of the Company at their startists and the Other Company at their startists and the Other Results and Startists.

eting held on 27 July 2021

By order of the Board For Dr. Reddy's Laboratories Limited

Place : Hyderabad Date : 27July 2021

GV Prasad Co-Chairman & Managing Direcor

Dr. REDDY'S LABORATORIES LIMITED

Regd. Office: 8-2-337, Road No.3, Banjara Hills, Myderabad - 500 034, Telangana, India CIN: L85195TG1984PLC004507, Tel: 91 40 4900 2900, Fax: 91 40 4900 2999

email: shares@drreddys.com, website: www.drreddys.com

